Kazia Therapeutics Seeks FDA Meeting for Paxalisib Conditional Approval in Glioblastoma Under Project FrontRunner Initiative
核心洞察
Kazia Therapeutics (搜索) plans to request an FDA Type C meeting to discuss overall survival data for paxalisib in newly diagnosed glioblastoma (搜索) patients, seeking conditional approval pathway under Project FrontRunner.
The company reported median overall survival of 15.54 months with paxalisib versus 11.89 months with standard care in unmethylated GBM (搜索) patients from a prespecified secondary analysis.
Kazia will propose initiating a post-approval Phase 3 confirmatory study before NDA submission, aligning with FDA's emphasis on overall survival as the gold standard endpoint in oncology.
Kazia Therapeutics (搜索) Limited announced its intention to request a follow-up Type C meeting with the U.S. Food & Drug Administration to discuss overall survival findings in newly diagnosed glioblastoma (搜索) patients treated with paxalisib and seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence's Project FrontRunner initiative.
The Sydney-based oncology company aims to leverage survival data from its investigational brain-penetrant PI3K (搜索)/Akt (搜索)/mTOR (搜索) pathway inhibitor to pursue a conditional approval pathway for one of the most lethal cancers with limited therapeutic options.
Survival Data Shows Promise in Aggressive Brain Cancer
In a prespecified secondary analysis announced in July 2024, newly diagnosed unmethylated GBM (搜索) patients treated with paxalisib demonstrated a median overall survival of 15.54 months (n = 54) compared to 11.89 months for concurrent standard of care (n = 46). This represents a 3.65-month improvement in median survival for patients with this aggressive brain tumor.
"GBM (搜索) remains one of the most lethal cancers with limited therapeutic options," said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics (搜索). "In line with the FDA Oncology Center of Excellence's Project FrontRunner initiative, we intend to engage the Agency to discuss whether the overall survival data generated in newly diagnosed GBM patients treated with paxalisib may be adequate to support a conditional approval pathway."
Aligning with FDA's Modernized Framework
The company's regulatory strategy reflects the FDA's recently issued draft guidance stating that overall survival is the "gold standard" endpoint in oncology and "should be prioritized as the primary endpoint when feasible," particularly in diseases with a short natural history where survival can be reliably assessed.
Project FrontRunner is an FDA Oncology Center of Excellence initiative encouraging sponsors to consider seeking approval of cancer drugs for advanced or metastatic disease in an earlier clinical setting, rather than the traditional approach of developing therapies only for patients who have exhausted available treatment options.
"Consistent with this framework, Kazia will propose initiation of the post-approval, randomized Phase 3 confirmatory study prior to submission of the NDA, ensuring that our regulatory strategy fully reflects the FDA's renewed emphasis on overall survival as the most meaningful endpoint for patients and clinicians," Dr. Friend stated.
Comprehensive Development Program
Paxalisib, licensed from Genentech in late 2016, has been the subject of ten clinical trials and was granted multiple FDA designations including Orphan Drug Designation for glioblastoma (搜索) in February 2018 and Fast Track Designation in August 2020. The drug also received Fast Track Designation in July 2023 for treating solid tumor brain metastases (搜索) harboring PI3K (搜索) pathway mutations in combination with radiation therapy.
A completed Phase 2/3 study in glioblastoma (搜索) (GBM (搜索)-Agile) was reported in 2024, with ongoing discussions for designing and executing a pivotal registrational study. Additional clinical trials involving paxalisib are ongoing in advanced breast cancer (搜索), brain metastases (搜索), diffuse midline gliomas (搜索), and primary central nervous system lymphoma (搜索).
"We are moving decisively to bring paxalisib forward in GBM (搜索) using the endpoints that matter most to patients and physicians," added Dr. Friend. "Our objective is to work collaboratively with the FDA under the guiding principles of Project FrontRunner to pursue a conditional approval in the front-line treatment setting of glioblastoma (搜索)."
The company notes that leading oncology companies have begun publicly referencing Project FrontRunner in successful FDA actions, underscoring the initiative's growing relevance for sponsors developing first-line or earlier-setting therapies.